Abiopharma

🔍 Lefebvre d'Ovidio Manfredi (Director)

Company: Arqit Quantum Inc. (ARQQ)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Sold 713 shares of Business Combination Warrants (right to buy) (Derivative)
  Date: 2026-04-15 | Code: S | Expires: 2026-09-03 | equity_swap_involved: 0 | shares_owned_after: 29,151.84 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 159 shares of Business Combination Warrants (right to buy) (Derivative)
  Date: 2026-04-16 | Code: S | Expires: 2026-09-03 | equity_swap_involved: 0 | shares_owned_after: 28,992.80 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: On September 19, 2024, Arqit Quantum Inc. (ARQQ) announced the implementation of a reverse stock split whereby every 25 outstanding ARQQ ordinary shares were consolidated into one ordinary share, par value $0.0025 per share. Each Business Combination Warrant has an exercise price of $11.50 and can be exercised at any time, at the holder's election, to purchase 0.04 of an ARQQ ordinary share on a post-reverse stock split basis, and cannot be exercised for fractional shares. Accordingly, on a post-reverse stock split basis holders of Business Combination Warrants are required to exercise at least 25 Business Combination Warrants in order to receive one whole ARQQ ordinary share at an aggregate exercise price of $287.50 per whole ARQQ ordinary share. The reporting person beneficially owns 724,820 Business Combination Warrants, which, if exercised in full, would be equivalent to 28,992.8 ARQQ ordinary shares on a post-reverse stock split basis.
• REMARKS: Due to the issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Securities Exchange Act of 1934 (the "Act"), the reporting person's transactions in the issuer's securities are exempt from Sections 16(b) and 16(c) of the Act.